In the News | Friends of Cancer Research

You are here

In the News

STAT - What’s key to the next cancer breakthrough? The answer may lie in pan-tumor biomarkers

Targeted cancer treatments, especially immunotherapies, are complex. Understanding in which patients they will work, and just as importantly in which they won’t, is not easy. However, when patients are matched with a treatment approach based on the genomic insights from his or her individual tumor profile, the outcomes can be significant.

 

Healio - Broader inclusion criteria could double the number of patients with lung cancer eligible for clinical trials

The use of expanded eligibility criteria would allow nearly twice as many people with non-small cell lung cancer to participate in clinical trials, according to data presented at ASCO Annual Meeting.

 

The study is the result of a joint project between ASCO and the nonprofit advocacy group Friends of Cancer Research, which issued recommendations for expanding clinical trial access.

OncoZine - Changing Clinical Trial Enrollment Criteria Dramatically Increases Participation of Eligible Patients with Lung Cancer

Restrictive eligibility criteria may limit or even jeopardize data generalizability of the trial results and opportunities for patients to participate in a clinical trial. [1][2]

 

And while the primary purposes of eligibility criteria are designed to protect the safety of patients participating in a clinical trial and to define the trial population, excessive or overly restrictive eligibility criteria can slow trial accrual, and limit understanding of the intervention’s benefit-risk profile.[2]

 

Everyday Health - New Data on Laparoscopic Surgery for Colon Cancer Metastases, and More News From the American Society of Clinical Oncology (ASCO) Annual Meeting

People with advanced colorectal cancer that has spread to the liver can undergo laparoscopic surgery instead of open surgery without affecting their chances of survival, according to data presented June 3 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

 

eCancer News - Immunotherapy drug found safe in treating cancer patients with HIV

The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab.

During an ASCO presentation concurrent with release of a study in JAMA Oncology, Fred Hutch researcher and lead author Dr. Tom Uldrick said that in nearly all cases it was safe to use the drug in patients with cancer and HIV.

 

POZ - Checkpoint Immunotherapy Is Safe and Effective for HIV-Positive People With Cancer

People living with HIV can safely use checkpoint inhibitors, a type of immunotherapy that unleashes T-cell activity against cancer, according to study results presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago.

 

Researchers reported that the PD-1 checkpoint blocker Keytruda (pembrolizumab) and the PD-L1 blocker Imfinzi (durvalumab) were safe and well tolerated in HIV-positive people with various types of cancer. Response rates were in line with those seen in HIV-negative people.

 

Cure - FDA's Project Facilitate Will Assist Requested Access to Unapproved Cancer Therapies

The Food and Drug Administration (FDA) revealed its pilot program, designed to assist oncologists and patients requesting access to unapproved therapies in the cancer space.

 

The two-pronged program is called Project Facilitate, run by the FDA Oncology Center of Excellence, and Expanded Access Navigator, which is operated by the Reagan-Udall Foundation for the FDA.

 

OncLive - Broader Trial Criteria Would Almost Double Eligibility in Advanced NSCLC

A broader set of clinical trial eligibility criteria proposed by the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research would nearly double the number of patients with advanced non-small cell lung cancer (aNSCLC) available for enrollment, according to findings presented at the 2019 ASCO Annual Meeting.

 

The ASCO Post - 2019 ASCO: Expansion of Clinical Trial Inclusion Criteria in Patients With Advanced NSCLC

A study that examined 10,500 health records of patients with advanced non–small cell lung cancer from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria—as proposed by ASCO and Friends of Cancer Research in 2017—would nearly double the percentage of patients eligible to enroll in clinical trials—from 52.3% to 98.5%. The expanded clinical trial eligibility criteria would allow patients with advanced NSCLC and brain metastases, previous or concurrent cancers, and limited kidney function to enroll in clinical trials.

Cancer Network - Is It Time to Change Clinical Trial Inclusion Criteria in Lung Cancer?

It may be possible to double the number of patients eligible for clinical trials for advanced non–small-cell lung cancer (NSCLC). A study looking at 10,500 health records of advanced NSCLC patients has found that the use of expanded clinical trial inclusion criteria would nearly double the percentage of patients eligible to enroll in clinical trials, from 52.3% to 98.5%. These results (abstract LBA108) were presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31–June 4 in Chicago.

Pages